Four new drugs to watch in 2021
View the latest OptumRx Drug Pipeline Insights Report.
OptumRx is pleased to provide a summary of notable new drug approvals expected for mid-2021. For this issue of the Drug Pipeline Insights Report, we will begin by highlighting a first-in-class treatment for those with chronic kidney disease and type 2 diabetes. Then a new oral treatment option for preventing migraine attacks. We close this period with a look at two drugs aimed at similar genetic liver conditions.
Don't want to read the full report? Download the brief summary.